HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS Pick For FDA Commissioner Is Crawford; Bush Announcement Pending

This article was originally published in The Tan Sheet

Executive Summary

HHS has recommended Virginia Tech Center for Food & Nutrition Policy Director Lester Crawford, PhD, to the White House as its choice for FDA commissioner.

You may also be interested in...

FDA Commissioner McClellan? HHS’ Thompson Says Nomination Is Imminent

The Bush Administration appears ready to move forward with the nomination of health advisor Mark McClellan, MD/PhD, as FDA commissioner

Food Safety: Improvements Necessary But Means Debated By Stakeholders

Food safety oversight in the U.S. would be best achieved by "designating" an existing federal agency as the single coordinating body rather than "creating" a new entity, the Food Marketing Institute told a Senate Government Affairs subcommittee Oct. 10.

FDA Preparing For Crawford? Lumpkin Named Acting Deputy Commissioner

The appointment of former Office of Review Management Director Murray Lumpkin, MD, as acting deputy commissioner makes him the agency's highest ranking physician.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts